Baseline serum testosterone and differential efficacy of bipolar androgen therapy and enzalutamide in the randomized TRANSFORMER trial

Competing interests

All authors declare that they have no conflicts of interest in relation to the article. The authors would like to disclose the following financial relationships that are not related to this article. J Luo has served as a paid consultant/advisor for Sun Pharma. J Luo has received research funding for his institution from Sanofi, Constellation, Calibr, and Cardiff Oncology and is a co-inventor of a technology owned by Johns Hopkins University and licensed to Qiagen and A&G. ES Antonarakis has served as a paid consultant/advisor for Sanofi, Dendreon, Janssen Biotech, ESSA, Merck, AstraZeneca, Clovis Oncology, Lilly, Bayer, and received honorarium from Sanofi, Dendreon, Medivation, Janssen Biotech, ESSA, Astellas Pharma, Merck, AstraZeneca, Clovis Oncology. E Antonarakis received research funding from Janssen Biotech, Johnson & Johnson, Sanofi, Dendreon, Aragon Pharmaceuticals, Exelixis, Millennium, Genentech, Novartis, Astellas Pharma, Tokai Pharmaceuticals, Merck, AstraZeneca, Clovis Oncology, Constellation Pharmaceuticals, as well as travel accommodations from Sanofi, Dendreon, Medivation. E Antonarakis is a co-inventor of a technology owned by Johns Hopkins University and licensed to Qiagen. S Denmeade has Stock and Other Ownership Interests in Sophiris Bio, served as Consultant/advisor for Sophiris Bio, and received travel accommodations from Sophiris Bio.

留言 (0)

沒有登入
gif